Latest Regenerative biomedicine Stories

- Alliance for Regenerative Medicine Launches Second, Expanded Annual Industry Report at Regen Med Investor Day - WASHINGTON, April 17, 2013 /PRNewswire/ -- The Regenerative Medicine Annual Report, released today at the Alliance for Regenerative Medicine's (ARM) first annual Regen Med Investor Day, provides an overview of the tremendous growth and progress in the regenerative medicine (RM) sector during the past year. The 70-page report includes in-depth information on RM products currently...

MONT-SAINT-GUIBERT, Belgium, April 11, 2013 /PRNewswire/ -- Trial Demonstrates Statistically Significant Improvements in Heart Function and Exercise Tolerance with Cardiopoietic Stem Cell Therapy Cardio3 BioSciences (C3BS) announces today the advanced publication of C-CURE (Phase II) trial results in the on-line edition of the Journal of the American College of Cardiology (JACC).1 The publication reported: - Statistically...

WINSTON-SALEM, N.C., March 11, 2013 /PRNewswire/ -- Tengion, Inc. (OTCQB: TNGN), a leader in regenerative medicine, today announced it will host a conference call and live audio webcast on Monday, March 18, 2013, at 9:00 a.m. EDT to provide a business update and discuss its fourth quarter and full year 2012 financial results. To participate in the call, please dial 1-866-543-6403 (domestic) or 1-617-213-8896 (international) and reference access code 98136968. The conference call...

-- Treatment being developed would use encapsulation to protect new insulin-producing cells derived from a stem cell precursor -- NEW YORK and SAN FRANCISCO, Feb. 13, 2013 /PRNewswire-USNewswire/ -- JDRF, the world's largest non-profit supporter of type 1 diabetes (T1D) research, and the California Institute for Regenerative Medicine (CIRM), California's stem cell agency, announced that they are providing additional funding for the development of a novel stem cell therapy by San...

Johns Hopkins Medicine Researchers at Johns Hopkins have devised a way to detect whether cells previously transplanted into a living animal are alive or dead, an innovation they say is likely to speed the development of cell replacement therapies for conditions such as liver failure and type 1 diabetes. As reported in the March issue of Nature Materials, the study used nanoscale pH sensors and magnetic resonance imaging (MRI) machines to tell if liver cells injected into mice survived over...

"The Center for regenerative medicine introduces Genorthix system," according to Roman Garcia PT. (PRWEB) December 25, 2012 "The Center for regenerative medicine introduces Genorthix system." according to Roman Garcia PT. "The Genorthix system combines the fractal geometric re-constitutive effect of ultra-sound energy with the re-hydrating and pain reliever properties contained in the Genorthix Penetrating Pain Reliever cream. Now available to the public for the...

WASHINGTON, Dec. 19, 2012 /PRNewswire/ -- The Alliance for Regenerative Medicine (ARM) today announced its first Regen Med Investor Day will take place on April 17, 2013. Co-hosted by leading financial firms Burrill & Company, Piper Jaffray and Maxim Group, this one-day meeting will provide institutional, strategic and venture investors' unique insight into the investment hypothesis for regenerative medicine-based therapeutics and tools. ARM's Regen Med Investor Day will include...

WASHINGTON, Dec. 18, 2012 /PRNewswire/ -- The Alliance for Regenerative Medicine (ARM), the international organization representing the interests of the regenerative medicine community, today announced that the third annual State of the Industry Briefing will take place on January 8, 2013 in San Francisco. The session will include two panels comprised of leading experts in the field. The first panel will provide an in-depth analysis of recent developments in regenerative medicine,...

WASHINGTON, Dec. 13, 2012 /PRNewswire/ -- The Alliance for Regenerative Medicine (ARM) today announced the formation of a Tissue Engineering and Biomaterials Committee (TEBC). The TEBC has been established to assemble the companies, academic institutions, and organizations within the Alliance for Regenerative Medicine that develop and commercialize tissue engineered and biomaterial based technologies. The primary purpose of the TEBC is to develop a better understanding of...

NEW YORK, Oct. 29, 2012 /PRNewswire/ -- IntelliCell BioSciences, Inc. ("Company") (SVFC) announced today that Myron Z. Holubiak has joined the IntelliCell Board of Directors. Mr. Holubiak is an accomplished biotech and pharmaceutical senior executive with over 30 years of industry experience including directing Roche Laboratories, a $2.8 billion dollar company with over 3,500 employees, as its President. Mr. Holubiak also serves as Director for Ventrus BioSciences, Inc. and Chairman...